Menu
Back to Journals » Vascular Health and Risk Management » Volume 5
Safety and efficacy of alteplase in the treatment of acute ischemic stroke
Authors Micieli G, Marcheselli S, Tosi PA
Published 8 May 2009 Volume 2009:5 Pages 397—409
DOI https://doi.org/10.2147/VHRM.S4561
Review by Single anonymous peer review
Peer reviewer comments 4
Giuseppe Micieli, Simona Marcheselli, Piera Angela Tosi
Neurology and Stroke Unit, IRCCS Istituto Clinico Humanitas, Rozzano (MI), italy
Abstract: After publication of the results of the National Institute of Neurological Disorders and Stroke study, the application of intravenous thrombolysis for ischemic stroke was launched and has now been in use for more than 10 years. The approval of this drug represented only the first step of the therapeutic approach to this pathology. Despite proven efficacy, concerns remain regarding the safety of recombinant tissue-type plasminogen activator for acute ischemic stroke used in routine clinical practice. As a result, a small proportion of patients are currently treated with thrombolytic drugs. Several factors explain this situation: a limited therapeutic window, insufficient public knowledge of the warning signs for stroke, the small number of centers able to administer thrombolysis on a 24-hour basis and an excessive fear of hemorrhagic complications. The aim of this review is to explore the clinical efficacy of treatment with alteplase and consider the hemorrhagic risks.
Keywords: rt-PA, acute ischemic stroke, intracranial hemorrhage
© 2009 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.